Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Pictured: A scientist works behind an FDA sign/Tay

FDA Tracker

Biocon Adds to Mounting Pressure on J&J’s Stelara as FDA Approves Biosimilar

In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024.

December 3, 2024

209 min read

Heather McKenzie

Contemporary art collage. Conceptual design. Making financial strategy. Employees sitting on company graph, creating analytics. Way to financial growth. Concept of business, brainstorming, team

Business

The Biggest Pharma Share Moves of the Year So Far

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.

November 27, 2024

9 min read

Annalee Armstrong

Podcast

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.

November 27, 2024

1 min read

Heather McKenzie

United States Supreme Court Building in Washington DC, USA.

Drug shortages

Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.

November 26, 2024

4 min read

Ben Hargreaves

Drug shortages

FDA Still Undecided About Shortage Status of Lilly’s Tirzepatide

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster weight-loss therapy.

November 22, 2024

2 min read

Tristan Manalac

Pictured: Eli Lilly's headquarters in Indianapolis

GLP-1

Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment

Eli Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the activin type IIA receptor to induce weight loss and boost muscle mass.

November 21, 2024

2 min read

Tristan Manalac

Photo of New York skyline during the daytime

Job Trends

5 Biopharma Companies Hiring in New York

Check out five New York companies hiring biopharma professionals like you, including 2025 Best Places to Work winners.

November 21, 2024

1 min read

Chantal Dresner

Pictured: An Eli Lilly Research Laboratories sign/

Cardiovascular disease

Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.

November 19, 2024

2 min read

Tristan Manalac

Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.

Radiopharma

Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space

The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.

November 18, 2024

2 min read

Nick Paul Taylor

JOBS